| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/15/2004 | WO2004005260A1 A-`7-halo-2-quino (xa-) linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents |
| 01/15/2004 | WO2004005259A1 Drug delivery system of substituted hydroxypyridine compound and conjugate of hydroxypyridine compound |
| 01/15/2004 | WO2004005258A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | WO2004005257A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | WO2004005256A2 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors |
| 01/15/2004 | WO2004005252A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 01/15/2004 | WO2004005249A1 Pyrrolidine derivatives as oxytocin antagonists |
| 01/15/2004 | WO2004005243A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 01/15/2004 | WO2004005229A1 Modulators of the glucocorticoid receptor |
| 01/15/2004 | WO2004004833A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 01/15/2004 | WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | WO2004004778A1 Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents |
| 01/15/2004 | WO2004004776A1 Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | WO2004004775A1 Novel drug compositions based on novel anticholinergics and inhibitors of egfr-kinase |
| 01/15/2004 | WO2004004772A1 Remedy for diabetes |
| 01/15/2004 | WO2004004770A1 Chemotactic factor inhibitor for modulating inflammatory reactions |
| 01/15/2004 | WO2004004763A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004745A1 Carbon dioxide external preparation and material for formation of carbon dioxide external preparation |
| 01/15/2004 | WO2004004736A1 Novel use of imidazotriazinones |
| 01/15/2004 | WO2004004735A1 Remedy comprising combination of levocabastine with pemirolast |
| 01/15/2004 | WO2004004733A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/15/2004 | WO2004004729A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | WO2004004725A2 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
| 01/15/2004 | WO2004004724A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | WO2004004720A1 3-`(hetero) arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors |
| 01/15/2004 | WO2004004718A1 Liquid dosage forms of acid labile drugs |
| 01/15/2004 | WO2004004712A1 Methods of treating microbial infections in humans and animals |
| 01/15/2004 | WO2004004702A2 Method to inhibit ischemia and reperfusion injury |
| 01/15/2004 | WO2004004701A1 Remedy for urinary frequency and urinary incontinence |
| 01/15/2004 | WO2004004690A1 Liquid dosage forms of proton pump inhibitors |
| 01/15/2004 | WO2004004665A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 01/15/2004 | WO2004004656A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | WO2004004652A2 Mitotic kinesin binding site |
| 01/15/2004 | WO2004004651A2 Therapeutic amides |
| 01/15/2004 | WO2004004648A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | WO2004004641A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 01/15/2004 | WO2004004629A2 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 01/15/2004 | WO2004004599A2 Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia |
| 01/15/2004 | WO2004004451A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | WO2003094831A3 Novel diazabicyclic biaryl derivatives |
| 01/15/2004 | WO2003092608A3 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 01/15/2004 | WO2003091247A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003082191A3 Substituted 2,3-diphenyl pyridines |
| 01/15/2004 | WO2003062191A8 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 01/15/2004 | WO2003057170A8 Oral insulin therapy |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2003049682A3 Composition and method for treating chronic allograft rejection |
| 01/15/2004 | WO2003039466A3 Method of treating estrogen responsive breast cancer |
| 01/15/2004 | WO2003019146A3 High throughput screening assays using fatty acid synthetic enzymes |
| 01/15/2004 | WO2002096866A3 Thiolalkyl benzoic acid derivatives |
| 01/15/2004 | WO2002072010A3 Taxane prodrugs |
| 01/15/2004 | WO2002042777A3 Modulation of the interaction between evh1 domains |
| 01/15/2004 | US20040010218 Injecting an aberrant tissue-selective photosensitizer into the bloodstream, exposing the aberrant tissue to light to activate the photosensitizer which increases the permeablitiy of the vasculature; injecting a chemotherapeutic agent |
| 01/15/2004 | US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders |
| 01/15/2004 | US20040010147 Cyclic amine compounds and pharmaceutical composition containing the same |
| 01/15/2004 | US20040010143 Viricides |
| 01/15/2004 | US20040010141 Antiinflammatory agents; anticancer agents; rheumatic disorders; cardiovascular disorders |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010047 Synergistic mixture of anticholesterol agents and coenzyme Q-10 |
| 01/15/2004 | US20040010029 Also benzothiophene derivatives; treating allergy, asthma, rhinitis, dermatitis, B-cell lymphomas, tumors and infections; modulating T helper cells, Th1/ Th2, and inhibiting the transcription of IL-4 |
| 01/15/2004 | US20040010027 Tumor angiogenesis and metastasis inhibition. |
| 01/15/2004 | US20040010023 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 01/15/2004 | US20040010022 2-aminooxazole derivatives |
| 01/15/2004 | US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma |
| 01/15/2004 | US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 01/15/2004 | US20040010010 Melanocortin receptor ligands |
| 01/15/2004 | US20040010008 Piperidine derivatives useful as CCR5 antagonists |
| 01/15/2004 | US20040010007 Also thio, sulfoxy and sulfonyl derivatives; imidazotetrazolopyrimidines and intermediates |
| 01/15/2004 | US20040010001 Methods and compositions for modulating cell proliferation and cell death |
| 01/15/2004 | US20040009997 Treating diseases in which HMG CoA reductase is implicated, such as hyperlipidemia, hypercholesterolemia and atherosclerosis |
| 01/15/2004 | US20040009996 4-(1,2- or 2,1-benzoxazol-5-yl)-2-aminopyrimidines |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009994 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 01/15/2004 | US20040009991 Calcium channel antagonistic activity; especially useful as analgesics |
| 01/15/2004 | US20040009988 Inhibiting hepatic production of apoprotein B-100 and microsomal triglyceride transfer protein to decrease VLDL and chylomicrons production |
| 01/15/2004 | US20040009986 Triglyceride depressant composition |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009983 Azaindoles |
| 01/15/2004 | US20040009980 Calcilytic compounds |
| 01/15/2004 | US20040009979 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 01/15/2004 | US20040009968 Indazole compounds useful as protein kinase inhibitors |
| 01/15/2004 | US20040009965 Treating hyperproliferative disorders |
| 01/15/2004 | US20040009963 Use of salmeterol and fluticasone propionate combination |
| 01/15/2004 | US20040009962 Combined estrogen blockade of the breast with exemestane and raloxifene |
| 01/15/2004 | US20040009950 Secreted human proteins |
| 01/15/2004 | US20040009930 Macrolide antibiotics |
| 01/15/2004 | US20040009906 Induction of antigen specific immunologic tolerance |
| 01/15/2004 | US20040009905 Templates consist of cyclized peptides containing at least two residues in said cyclized peptide are joined by a naphthyl ring; and having bonded to it a linear peptide |
| 01/15/2004 | US20040009901 Identifying and administering an agent that enhances NADPH oxidase activity; diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency |
| 01/15/2004 | US20040009895 Also stimulating interleukin-18 or GM-CSF by administering lactoferrin |
| 01/15/2004 | US20040009505 A pair of genetic engineered primers for the mutagenic amplification, therapeutic treatment |
| 01/15/2004 | US20040009475 Tumor cells to cytotoxic chemotherapeutic agents, especially antimetabolites and agents that damage DNA; excision repair cross-complementing (ERCC1) gene; thymidylate synthase (TS) |
| 01/15/2004 | US20040009248 Method for improving the cell protection |
| 01/15/2004 | US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 01/15/2004 | US20040009231 hGH (human growth hormone) formulations for pulmonary administration |
| 01/15/2004 | US20040009189 Antimutagenic effects of ganoderma lucidum spores |